Source: https://www.federalregister.gov/articles/2009/02/17/E9-3150/schedules-of-controlled-substances-placement-of-tapentadol-into-schedule-ii
Timestamp: 2015-03-03 00:37:35
Document Index: 116122946

Matched Legal Cases: ['§ 201', '§ 201', 'art 1301', '§ 1301', '§ 1302', 'art 1303', '§ 1304', '§ 1304', '§ 1304', 'art 1305', '§ 1306', 'art 1312', '§ 3', '§ 804', '§ 201', 'art 1308', '§ 1308']

Federal Register | Schedules of Controlled Substances: Placement of Tapentadol Into Schedule II
Schedules of Controlled Substances: Placement of Tapentadol Into Schedule II
Dates: Written comments must be postmarked on or before March 19, 2009, and electronic comments must be sent on or before midnight Eastern time March 19, 2009.
Comments Close: 03/19/2009
74 FR 7386
-7388 (3 pages)
Docket No. DEA-319P
Document Number: E9-3150
Shorter URL: https://federalregister.gov/a/E9-3150 Related Topics
This proposed rule is issued by the Deputy Administrator of the Drug Enforcement Administration (DEA) to place the substance tapentadol, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible, into schedule II of the Controlled Substances Act (CSA). This proposed action is based on a recommendation from the Assistant Secretary for Health of the Department of Health and Human Services (DHHS) and on an evaluation of the relevant data by DEA. If finalized, this action would impose the regulatory controls and criminal sanctions of schedule II on those who handle tapentadol and products containing tapentadol.
Requirements for Handling Tapentadol
Written comments must be postmarked on or before March 19, 2009, and electronic comments must be sent on or before midnight Eastern time March 19, 2009.
To ensure proper handling of comments, please reference “Docket No. DEA-319” on all written and electronic correspondence. Written comments sent via regular or express mail should be sent to the Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODL, 8701 Morrissette Drive, Springfield, Virginia 22152. Comments may be sent to DEA by sending an electronic message to dea.diversion.policy@usdoj.gov. Comments may also be sent electronically through http://www.regulations.gov using the electronic comment form provided on that site. An electronic copy of this document is also available at the http://www.regulations.gov Web site. DEA will accept electronic comments containing MS Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept any file format other than those specifically listed here.
Personal identifying information and confidential business information identified and located as set forth above will be redacted and the comment, in redacted form, will be posted online and placed in the DEA's public docket file.
Please note that the Freedom of Information Act applies to all comments received. If you wish to inspect the agency's public docket file in person by appointment, please see the FOR FURTHER INFORMATION CONTACT paragraph.
On November 20, 2008, the Food and Drug Administration (FDA) approved tapentadol for marketing in the United States as a prescription drug product for the treatment of moderate-to-severe acute pain. Tapentadol is a new molecular entity with centrally-acting analgesic properties.
Tapentadol has dual modes of action namely, mu (μ) opioid receptor agonistic action and inhibition of reuptake of norepinephrine at the norepinephrine transporter. The chemical name of its monohydrochloride salt form is 3-[(1 R,2 R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol hydrochloride.
Tapentadol shares substantial pharmacological effects and abuse potential with other schedule II opioid analgesics, e.g., morphine, oxycodone, and hydromorphone. Tapentadol has rewarding and reinforcing effects similar to those of morphine in animal models. It generalizes to the discriminative stimulus effects of morphine in rats and monkeys. Tapentadol, similar to morphine, produced conditioned place preference in rats, and this effect was antagonized by naloxone (anopioid receptor antagonist). In a clinical study with opioid-experienced non-dependent subjects, the subjective scores for drug liking of a single dose of tapentadol (50, 100 and 200 mg) were comparable to equianalgesic doses of hydromorphone (4, 8, and 16 mg). In clinical studies, tapentadol showed an adverse event profile similar to other schedule II opioids. The most commonly reported adverse events are nausea, dizziness, vomiting, somnolence, vertigo, and headache. In a clinical study in which the patients received equianalgesic doses of tapentadol or oxycodone for 90 days, the reports of withdrawal symptoms were comparable for both treatment groups upon discontinuance of administration. The ability of tapentadol to produce psychological dependence is suggested by a level of drug liking comparable to that produced by hydromorphone.
Since tapentadol is a new molecular entity, there has been no evidence of diversion, abuse, or law enforcement encounters involving the drug. On November 13, 2008, the Assistant Secretary for Health, DHHS, sent the Deputy Administrator of DEA a scientific and medical evaluation and a letter recommending that tapentadol be placed into schedule II of the CSA. Enclosed with the November 13, 2008, letter was a document prepared by the FDA entitled, “Basis for the Recommendation for Control of Tapentadol in Schedule II of the Controlled Substances Act.” The document contained a review of the factors which the CSA requires the Secretary to consider (21 U.S.C. 811(b)).
The factors considered by the Assistant Secretary of Health and the DEA with respect to tapentadol were:
Based on the recommendation of the Assistant Secretary for Health, received in accordance with § 201(b) of the Act (21 U.S.C. 811(b)), and the independent review of the available data by DEA, the Deputy Administrator of DEA, pursuant to §§ 201(a) and 201(b) of the Act (21 U.S.C. 811(a) and 811(b)), finds that:
(1) Tapentadol has a high potential for abuse;
(2) Tapentadol currently has accepted medical use in treatment in the United States; and
(3) Abuse of tapentadol may lead to severe psychological or physical dependence.
Based on these findings, the Deputy Administrator of DEA concludes that tapentadol, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible, warrants control in schedule II of the CSA. (21 U.S.C. 812 (b)(2))
Interested persons are invited to submit their comments, objections or requests for a hearing with regard to this proposal. Requests for a hearing should state, with particularity, the issues concerning which the person desires to be heard. All correspondence regarding this matter should be submitted to the DEA to the address provided above. In the event that comments, objections, or requests for a hearing raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing.
Requirements for Handling Tapentadol Back to Top
If this rule is finalized as proposed, tapentadol would be subject to the CSA regulatory controls and administrative, civil and criminal sanctions applicable to the manufacture, distribution, dispensing, importing, and exporting of a schedule II controlled substance, including the following:
Registration. Any person who manufactures, distributes, dispenses, imports, exports, engages in research or conducts instructional activities with tapentadol, or who desires to manufacture, distribute, dispense, import, export, engage in instructional activities or conduct research with tapentadol, would be required to be registered to conduct such activities in accordance with Part 1301 of Title 21 of the Code of Federal Regulations (CFR).
Security. Tapentadol would be subject to schedule II security requirements and must be manufactured, distributed and stored in accordance with §§ 1301.71, 1301.72(a), (c), and (d), 1301.73, 1301.74, 1301.75(b) and (c), 1301.76 and 1301.77 of Title 21 of the CFR.
Labeling and Packaging. All labels and labeling for commercial containers of tapentadol which are distributed after finalization of this rule would be required to comply with requirements of §§ 1302.03-1302.07 of Title 21 of the CFR.
Quotas. Quotas for tapentadol would be established pursuant to part 1303 of Title 21 of the CFR.
Inventory. Every registrant required to keep records and who possesses any quantity of tapentadol would be required to keep an inventory of all stocks of tapentadol on hand pursuant to §§ 1304.03, 1304.04 and 1304.11 of Title 21 of the CFR. Every registrant who desires registration in schedule II for tapentadol would be required to conduct an inventory of all stocks of the substance on hand at the time of registration.
Records. All registrants would be required to keep records pursuant to §§ 1304.03, 1304.04, 1304.21, 1304.22, and 1304.23 of Title 21 of the CFR.
Reports. All registrants required to submit reports to the Automation of Reports and Consolidated Order System (ARCOS) in accordance with § 1304.33 of Title 21 of the CFR would be required to do so for tapentadol.
Orders for tapentadol. All registrants involved in the distribution of tapentadol would be required to comply with the order form requirements of part 1305 of Title 21 of the CFR.
Prescriptions. All prescriptions for tapentadol or prescriptions for products containing tapentadol would be required to be issued pursuant to 21 CFR § 1306.03-1306.06 and 1306.11-1306.15.
Importation and Exportation. All importation and exportation of tapentadol would need to be in compliance with part 1312 of Title 21 of the CFR.
Criminal Liability. Any activity with tapentadol not authorized by, or in violation of, the CSA or the Controlled Substances Import and Export Act occurring on or after finalization of this proposed rule would be unlawful.
The Deputy Administrator, in accordance with the Regulatory Flexibility Act (5 U.S.C. 601-612), has reviewed this proposed rule and by approving it certifies that it will not have a significant economic impact on a substantial number of small entities. Tapentadol products will be prescription drugs used for the treatment of moderate-to-severe acute pain. Handlers of tapentadol will also handle other controlled substances used to treat pain which are already subject to the regulatory requirements of the CSA.
This regulation meets the applicable standards set forth in §§ 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
This rulemaking does not preempt or modify any provision of state law; nor does it impose enforcement responsibilities on any state; nor does it diminish the power of any state to enforce its own laws. Accordingly, this rulemaking does not have federalism implications warranting the application of Executive Order 13132. Unfunded Mandates Reform Act of 1995
This rule is not a major rule as defined by § 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act). This rule will not result in an annual effect on the economy of $100,000,000 or more; a major increase in costs or prices: or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign based companies in domestic and export markets.
Under the authority vested in the Attorney General by § 201(a) of the CSA (21 U.S.C. 811(a)), and delegated to the Administrator of the DEA by the Department of Justice regulations (28 CFR 0.100), and redelegated to the Deputy Administrator pursuant to 28 CFR 0.104, the Deputy Administrator hereby proposes that 21 CFR part 1308 be amended as follows:
21 U.S.C. 811, 812, 871(b) unless otherwise noted.
2. Section 1308.12 is amended in the table by adding a new paragraph (c)(28) to read as follows:
§ 1308.12 Schedule II.
[FR Doc. E9-3150 Filed 2-13-09; 8:45 am]